Making a difference

Droia Ventures is a specialist investor, dedicated to making an impact and save patient lives. We invest in novel science and innovative approaches to bring promising drug candidates to patients, and accelerate their progress by actively supporting young drug development companies to achieve clinical proof of concept with their lead programs. We have an in-house team of experts and drug development professionals who follow our companies closely and provide hands-on support.

Droia invests in early financing rounds and also incubates new companies. Operating from Luxembourg and Belgium, Droia invests globally.

Breakthrough focus

For life science companies, ultimate success should be measured in effective patient benefit. Droia invests in companies that develop the most promising and impactful therapies.

Promising therapies will have a material impact on patient prognosis, measured as a function of the severity of the unmet medical need addressed, the improvement in therapeutic benefits as compared to standard of care, and the feasibility of development.

Novel science can innovate in terms of mechanism of action, target, modality, specificity,… Above all, novel therapies should be sufficiently differentiated to earn their place among competing therapies in the future standard of care.

Getting it done

Droia actively participates in the development of the portfolio companies. We aim to support portfolio companies at least up to clinical proof of concept. To this end, Droia’s team has experience in translational science, clinical development and company building. Droia’s team can assist where useful on scientific, preclinical, clinical & CMC development, on IP & regulatory affairs, on licensing, legal, finance & transactions, and on general company building. Droia’s network of life science leaders gives us access to top-level institutions and KOL’s around the world and allows our portfolio companies to benefit from a global knowledge base.

Portfolio

Investment Team

Janwillem Naesens – Partner at DROIA

  • M.Sc. Engineering, University of Leuven
  • MBA, INSEAD
  • McKinsey & Company
  • Waterland Private Equity

* representing Wepaven BV

Janwillem Naesens *

Managing Partner Droia
DROIA-Luc-Verhelst-R

  • M.Sc. Bio-Engineering, University of Leuven
  • Founder / former owner of Verelst real estate group
  • Seasoned investor in small and big biotech, venture capital
  • Founder of the Anti Cancer Fund and the Verelst Uterine Cancer Fund

Luc Verelst

Founder & Chairman
DROIA-Luc-Dochez

  • Pharm.D., University of Leuven
  • MBA, Vlerick Management School
  • Arthur D. Little
  • TiGenix
  • Prosensa
  • Tusk Therapeutics
  • Independent board member Erytech, Pharvaris

* representing Primix Bio Ventures BV

Luc Dochez *

Managing Partner, Genetic Disease
DROIA-Lionel-De-Hemptinne

  • Msc. Business Engineering, Université Catholique de Louvain
  • Executive Master in Finance, Solvay Business School
  • ING Bank, Corporate Banking
  • Floridienne Group, CFO

* representing Axis Advice SRL

Lionel de Hemptinne *

Chief Financial Officer
DROIA-Matthias-De-Witte

  • Master of laws, University of Leuven
  • M.Sc. law and finance, Oxford University and Saïd Business School
  • Cleary Gottlieb Steen & Hamilton
  • Freshfields Bruckhaus Deringer
  • Etex Group

* representing MARA Consulting BV

Matthias De Witte *

General Counsel
DROIA-Sandra-Schoors

  • M. Sc. Biomedical Sciences, University of Leuven
  • PhD Biomedical Sciences – Angiogenesis and Metabolism, University of Leuven
  • Starter Fellowship Emmanuelle van der Schueren, Vlaamse Liga tegen Kanker
  • PhD fellow IWT & Post-doc fellow FWO
  • Nominee Eos Pipet
  • Recipient BiR&D Multidisciplinary PhD Award
  • Scientific publications in e.g. Nature, Cell, Cell Metabolism

Sandra Schoors

Principal
DROIA-Elke-Van-Oudenhove-nieuw

  • Studentship Wellcome Sanger Institute, Cambridge, UK
  • Lab Tech, Center for Medical Genetics, Ghent University, BE
  • PhD Medical Sciences, DNA damage in cancer, University of Cambridge, UK
  • Postdoctoral Fellow, novel drug targets in a rare cancer, New York University Langone Health, USA
  • Recipient Cancer Research UK PhD Fellowship
  • Scientific publications in e.g. JNCI, Oncotarget, Eur J Hum Genet

Elke van Oudenhove

Scientific Analyst
DROIA-Matthias-Van-Woensel

  • M. Sc. Biomedical Sciences, University of Leuven
  • PhD Biomedical Sciences – Tumor Immunology, University of Leuven
  • PhD Pharmaceutical Sciences – Polymers, ULB
  • PhD fellow IWT
  • Recipient VCU RDD Peter R. Byron Graduate Student Award
  • Belgian Brain Tumor Support
  • Scientific publications in e.g. EMBO Mol Med, Oncoimmunology, Journal of Controlled Release

Matthias Van Woensel

Principal
DROIA-Joke-Vereecken

  • MSc. Business Engineering, University of Leuven
  • CFA – level I
  • Ernst & Young, M&A advisory
  • Corporate finance, M&A, BD, structuring, tax & legal, modeling & valuation
  • Tusk Therapeutics, interim CFO

Joke Vereecken

Principal

Careers

Droia is currently recruiting for its investment and development team. The team scouts for new opportunities, evaluates companies and projects, manages the investment and exit process, and works with the portfolio companies on their progress.

Team members work closely with the portfolio companies at management or board level, and play a hands-on role in all aspects of the drug development process.

Droia is an entrepreneurial environment, where everyone is above all committed to making things happen.

Applicants should have relevant experience in biomedical science, drug development and/or life science investing.

Droia SA

27, Boulevard Prince Henri
L-1724 Luxembourg
Luxembourg

  Tel. +352 203 01 236

Droia NV

Brusselsesteenweg 11
1860 Meise
Belgium

  Tel. +32 2 880 67 30